COVID-19 studies are our top priority. For all other studies, we recommend commencing the registration process concurrently with your ethics submission and allowing at least 8 weeks for registration to be completed from date of first submission as we are experiencing 4 week turn-around time in review of submissions and resubmissions. We currently do not have the capacity to expedite reviews.

Note also there are additional delays to review of updates. We appreciate your patience.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from

For full trial details, please see the original record at

Registration number
Ethics application status
Date submitted
Date registered
Date last updated

Titles & IDs
Public title
Safety and Preliminary Efficacy of ATG-017 Monotherapy in Advanced Solid Tumors and Hematological Malignancies
Scientific title
A Phase I, Open-Label, Multi-Center Dose Finding Study to Investigate the Safety, Pharmacokinetics, and Preliminary Efficacy of ATG-017 Monotherapy in Patients With Advanced Solid Tumors and Hematological Malignancies
Secondary ID [1] 0 0
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Solid Tumor 0 0
Hematological Malignancy 0 0
Condition category
Condition code
Cancer 0 0 0 0
Leukaemia - Acute leukaemia
Cancer 0 0 0 0
Leukaemia - Chronic leukaemia

Study type
Description of intervention(s) / exposure
Treatment: Drugs - ATG-017

Experimental: ATG-017 - ATG-017 will be administered orally on an empty stomach QD in the first cohort of solid tumors group and BID 12 hours apart (no food or drink other than water for 2 hours prior to, and for 1 hour after study treatment administration) in other cohorts. All doses of ATG-017 should be taken at approximately the same time each day. Patients will receive study treatment in 21-day cycles.

Treatment: Drugs: ATG-017
Dosing will begin at 5 mg once a day (QD) ATG-017 as starting dose. A cycle of study treatment will be defined as 21 days.

Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Primary outcome [1] 0 0
AEs/SAEs - Toxicity will be graded according to the NCI CTCAE, Version 5.0.
Timepoint [1] 0 0
18 months
Secondary outcome [1] 0 0
Plasma concentrations - Venous blood samples for determination of total concentrations of ATG 017 in plasma to characterise the PK profile of ATG-017 for a particular dose level
Timepoint [1] 0 0
18 months
Secondary outcome [2] 0 0
Overall Response Rate (ORR) - To determine the overall response rate according to RECIST1.1, Chenson 2014, IWG 2003 and 2006
Timepoint [2] 0 0
18 months
Secondary outcome [3] 0 0
DOR - Duration of time from first occurrence of CR or PR until the first date that disease progression is objectively documented
Timepoint [3] 0 0
18 months
Secondary outcome [4] 0 0
Progression-Free Survival (PFS) - The time from the first dose date until disease progression or death from any cause
Timepoint [4] 0 0
18 months

Key inclusion criteria
1. Provision of signed and dated, written informed consent prior to any study specific
procedures, sampling and analyses.

2. Aged at least 18 years.

3. Patient must have a documented activating alteration of the RAS-MAPK pathway.

4. Histological or cytological confirmation of a solid tumour.

5. Patients with hematological malignancies.

6. Patient with solid tumors must have at least 1 lesion, not previously irradiated.

7. Estimated life expectancy of minimum of 12 weeks.

8. Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1.

9. Ability to swallow and retain oral medication.
Minimum age
18 Years
Maximum age
No limit
Both males and females
Can healthy volunteers participate?
Key exclusion criteria
1. Central nervous system metastatic disease, leptomeningeal disease, or metastatic cord

2. Prior ATG-017 administration in the present study.

3. Prior treatment with an ERK1/2 inhibitor.

4. Prior major surgery within 28 days of the first dose of study treatment or minor
surgical procedures =7 days.

5. Patients receiving unstable or increasing doses of corticosteroids.

6. As judged by the investigator, any evidence of severe or uncontrolled systemic

7. Active infection including hepatitis B, and/or hepatitis C.

8. Known history of human immunodeficiency virus (HIV) infection.

9. Inadequate bone marrow reserve or organ function


Study design
Purpose of the study
Allocation to intervention
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?

Intervention assignment
Single group
Other design features
Phase 1
Type of endpoint(s)
Statistical methods / analysis

Recruitment status
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Date of last participant enrolment
Date of last data collection
Sample size
Accrual to date
Recruitment in Australia
Recruitment state(s)
Recruitment hospital [1] 0 0
Peter MacCallum Cancer Centre - East Melbourne
Recruitment hospital [2] 0 0
Austin Hospital - Heidelberg
Recruitment hospital [3] 0 0
Alfred Hospital - Melbourne
Recruitment hospital [4] 0 0
Scientia Clinical Research - Randwick
Recruitment hospital [5] 0 0
Chris O'Brien Lifehouse - Sydney
Recruitment postcode(s) [1] 0 0
3002 - East Melbourne
Recruitment postcode(s) [2] 0 0
3084 - Heidelberg
Recruitment postcode(s) [3] 0 0
3004 - Melbourne
Recruitment postcode(s) [4] 0 0
- Randwick
Recruitment postcode(s) [5] 0 0
- Sydney

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Antengene Therapeutics Limited

Ethics approval
Ethics application status

Brief summary
This is a Phase I, multi-center, open-label study of ATG-017 administered orally, alone in
patients with advanced solid tumors and hematological malignancies. The study design includes
a Dose Escalation Phase and Dose Expansion Phase.
Trial website
Trial related presentations / publications
Public notes

Principal investigator
Name 0 0
Jiao Kuang, MD
Address 0 0
Medical Monitor
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Shimin Sun Sun, M.D.
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

Summary results
For IPD and results data, please see